Investment & Operations Platform for Innovative Therapies

Transforming Scientific Innovation into Pharma-Ready Therapeutic Solutions

THERAVION bridges the gap between breakthrough science and clinical-stage assets — combining capital, operational leadership, and translational expertise in a single integrated platform.

Between today and 2030, the expected loss of patent exclusivity will impact roughly 200 medicines — around 70 of them blockbusters — putting €250–300+ billion in annual revenues at risk. As internal R&D productivity declines, large pharmaceutical companies are increasingly dependent on externally sourced innovation, with total M&A deal value growing from roughly €191B in 2024 to roughly €240B in 2025.

Learn More Request a Meeting

About

Introducing THERAVION

A European Operator-Led Venture Fund for Early-Stage Life Sciences

📈

What We Are

A European venture fund investing in early-stage (pre-IND and IND-ready) drugs and medical devices across oncology, neurology, rare diseases, immunology, and aesthetics.

🤝

Founded by Pharma Veterans

One of the few Healthcare VC funds co-founded by two former global pharma executives with hands-on operator experience across the full drug development lifecycle.

Dr. Sotirios Stergiopoulos

Ipsen CMO · Bayer · Celgene · Novartis · Shire

Dr. George Carystinos

EY Partner · Ipsen GM · VP NPP · Deloitte

🌐

Network & Pipeline

A broad global network of subject matter experts, KOLs, and academic researchers spanning Europe and selective Asia.

Already identified 4 potential molecules under active examination across autoimmune, cardiovascular, oncology, and hematology.

20+
Years pharma leadership
6
Therapeutic focus areas
4
Molecules identified
EU + Asia
Geographic focus

The Thesis

Why the Existing Models Fall Short

Scientific innovation is accelerating. Yet translational execution remains fragmented across all incumbent models — creating a structural opportunity.

🏛️

Academic Innovation

  • Strong scientific discovery
  • Limited development know-how
  • Translational execution gaps
💰

Traditional VC

  • Primarily financing-focused
  • Limited operational expertise
  • Less equipped for therapeutic advancement
🔬

Standalone Biotech

  • R&D operations know-how
  • Infrastructure & bandwidth limits
  • Capital inefficiency challenges
🏢

Large Pharma

  • Strong R&D and commercial engines
  • Dependent on external innovation
  • Organizational complexity barriers
THERAVION takes on scientific innovation and advances it in a way that is customized to each asset.

The Platform

The THERAVION Unique Value

An Integrated Platform for Therapeutic Asset Creation, Advancement, and Strategic Value Realization.

Theravion Capability Wheel

Focus Areas

Areas of Therapeutic Interest

A disciplined focus on therapeutic areas with significant unmet need and proven exit potential. Theravion continues to monitor therapeutic advances, and is open to all early-stage opportunities that may have significant impact.

🧬

Oncology

Cell therapies (CAR-T/CAR-NK), antibody-drug conjugates with novel linker technologies, and radiopharmaceuticals targeting alpha-emitters for precision treatment.

CAR-T · ADCs · Radiopharmaceuticals
🧠

Neurology

Targeting neuroinflammation and novel protein misfolding pathways in neurodegenerative disease, plus gene therapy with vectors crossing the blood-brain barrier.

Neurodegeneration · Gene Therapy
🛡️

Immunology

Autoimmune platforms that promote immune tolerance rather than broad suppression — targeting functional cures by re-training the immune system.

Autoimmune · Tolerance Induction
🔎

Rare Diseases

Monogenic diseases and conditions with clear biomarkers, enabling fast proof-of-concept with potential one-time curative treatments.

Orphan · Monogenic · Biomarker-driven
✨

Medical Aesthetics

Exosome-based therapies and biomaterials stimulating the body's own collagen, meeting demand for natural, biology-driven long-lasting results.

Exosomes · Regenerative Tech
🤖

Medical Devices

Specialized robotic surgery platforms and AI-powered diagnostics focused on predictive analytics guiding clinical decision-making.

Robotic Surgery · AI Diagnostics

Development Approach

Operational & Translational De-Risking

Systematically reducing scientific, development, and strategic risk at every stage of asset advancement.

01

Scientific Validation

  • Mechanism validation
  • Therapeutic fit assessment
  • Translational relevance
02

Development & Regulatory

  • Staged R&D strategy
  • Clinical pathways
  • Regulatory coordination
03

Early Clinical Validation

  • Study design & planning
  • Financial optimization
  • Early clinical study readouts
04

Strategic Positioning

  • Pharma alignment
  • Commercial assessment
  • Partnership readiness

Program Progression ▸

Leadership

The Leadership Team

Deep pharmaceutical, clinical, and therapeutic development expertise across two decades of biopharma leadership.

Dr. Sotirios Stergiopoulos
Dr. Sotirios G. Stergiopoulos
MD, MBEE, FACP · Co-Founder
Oncology Biotech Founder Clinical Dev

A physician executive and oncology innovator with 20+ years across biopharma and clinical development. Founder of Coiled Therapeutics (LSE), A2A Pharmaceuticals, and Biomea Fusion (NASDAQ). Former CMO at Ipsen, where he led global oncology and rare disease portfolios. Clinical training at Harvard Medical School, Albert Einstein College, and the NIH.

Ipsen Bayer Celgene Novartis Shire
Dr. George Carystinos
Dr. George Carystinos
PhD, MBA · Co-Founder
Healthcare Strategy BD & Partnerships NPP

Health and life sciences executive with 20+ years of global experience across pharmaceuticals, consulting, and commercialization. Partner at EY (Head of Health & Life Sciences), GM at Ipsen Greece/Cyprus/Israel, VP Global New Product Planning at Ipsen, and Principal-level roles at Deloitte NY & Switzerland. PhD (honors) from McGill University Faculty of Medicine; MBA from Wharton.

Ipsen EY Deloitte

Get in Touch

Contact THERAVION

For investor inquiries, partnership discussions, or asset submissions, reach our leadership directly.

Dr. Sotirios G. Stergiopoulos

✉️

sotirios@theravionbio.com

📞

GR: +30 698 506 2473
US: +1 718 570 5029

Dr. George Carystinos

✉️

george@theravionbio.com

📞

GR: +30 694 683 7001
US: +1 646 334 1941

🌐

General Inquiries

info@theravionbio.com  ·  www.theravionbio.com

** Confidential. This material is intended solely for qualified investors and may not be shared or presented without prior consent from Theravion PC. **
This document does not constitute an offer to sell or a solicitation of an offer to buy interests in any fund. Past performance is not indicative of future results.